There's a merger boom going on right now, but amid all the gloom, no one's really paying much attention.
It could be because the sector in question has had a miserable few years itself, while almost every other industry was partying. But now, at last, after a long stay in the doldrums, the biotech sector is finally coming back into the spotlight.
There has been a mass of deals in the US, while on this side of the Atlantic, a number of attractive little biotech stocks have been approached or agreed bids in the last couple of months.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
And the good news is, it's still not too late to join in the party
Biotech sector is undergoing a merger boom
It's been a great couple of months for biotech stocks. In the US, Swiss group Roche made a $43bn bid for biotech giant Genentech last month (since rejected), while Bristol-Meyers offered $4.5bn for fellow biotech ImClone.
And over here, vaccine specialist Acambis has agreed a 190p-a-share offer from France's Sanofi-Pasteur. Meanwhile both Protherics and Oxford Biomedica, a couple of other small pharma stocks, have revealed bid approaches.
I hold both Protherics and Acambis in my own portfolio, and they're stocks I've tipped in the past. However, just to demonstrate what a volatile sector biotech can be, when I last tipped Protherics in MoneyWeek in February, the shares were trading at around 50p. By the time the bid news had came around, they had slipped for no particular reason to as low as 27p at one point. They're now at around 56p but that's a lot of volatility to endure for a 10% gain or so.
What does this show (apart from that share tipping is a mug's game)? Well, while anyone who bought Protherics at the low has now doubled their money, the chances of most of us getting that lucky are low. And even if you do it once, chances are the next biotech you stick your money into will turn out to be a complete dud. As Andy Smith, manager of the Axa Framlington Biotech fund, told me last week: "I see 400 companies a year. Every one of their chief executives reckons they've got a $1bn product." That's what's known as a blockbuster in the pharma trade. But "the truth is that most drugs fail."
Enjoying this article? Sign up for our free daily email, Money Morning, to receive intelligent investment advice every weekday. Sign up to Money Morning.
Why the trend is likely to continue
However, the M&A activity is likely to continue. Big pharmaceutical companies are running out of bestsellers. As Smith points out, in 60-odd years of modern medicine, most of the "easy cures" or treatments for common conditions have been found. The pharma industry has picked all "the low-hanging fruit" and now traditional methods of finding drugs no longer produce as many good candidates as they once did.
That means attention is shifting now to management of complex conditions such as cancer, HIV and other, rarer diseases the type of diseases that biotech companies focus on. And one of the easiest ways for big pharmaceutical companies to build their presence in the sector is simply to buy up promising biotech players.
If you're really keen to punt on individual stocks, there are plenty of tips around. Shares magazine likes the look of Concateno and IS Pharma. The Times meanwhile, recommends ProStrakan. As for Smith, he reckons Shire Pharmaceuticals is worth a look, as one of the few biggish pharma stocks that has managed to build itself a solid biotech arm through some canny acquisitions.
The easiest way to profit from the biotech boom
But if you would rather earn a decent profit from a trend which looks very likely to continue, I'd suggest avoiding the stock-picking which is really just pure speculation at this end of the market and go for a fund.
You could take a look at Smith's fund, a unit trust (visit www.axaframlington.com for more details). It holds around 70 stocks, and by fund management standards he's not afraid to take big bets, with his top holding, Gilead Sciences, currently accounting for nearly 9% of the portfolio. As regular readers will know, we don't tend to be keen on unit trusts because of the higher fees, though sometimes they can be the only way into a specialist sector.
But alternative options in this case include two London-listed investment trusts, the Biotech Growth Trust (BIOG)or the Finsbury Worldwide Pharmaceutical Trust (FWP).Or you could buy an ETF such as the iShares Nasdaq Biotechnology Index (US:IBB) it's purely US-focused, but then that's where the largest concentration of biotech stocks are listed.
You can find out more on these in the latest issue of MoneyWeek, out today. And there's more on the pharma sector in general, in our recent cover story: Turning to drugs. If you're not already a subscriber, subscribe to MoneyWeek magazine.
Our recommended articles for today...
How to value rock-solid, world-beating stocks
Few companies are recession-proof, but there are some that are likely to remain in a strong position whatever happens: large, powerful companies that dominate their markets. But how do you know what you should be paying for these companies' stocks?
Why everything has changed for savers
The greed of banking executives has changed things for all of us. Bank balance sheets are in tatters. The risk to savers of having money on deposit has changed for the worse. But how much worse do things have to get before depositors lose money - or lose ready access to their capital?
-
FTSE 100 hits record highs – why is it rising and will we see more gains?Advice UK equities have been described as unloved for a long time but as the FTSE 100 hits new highs, we explain if now is the time to buy British.
-
How to invest in copperIt may be time to invest in copper as the red metal appears poised for a big jump. Dominic Frisby looks at what should investors should buy
-
A beginner’s guide to bitcoin: what is bitcoin?Beginners' Guides As a completely novel concept for many people, bitcoin can take a little effort to get to grips with. In the first of a short series on the cryptocurrency, Dominic Frisby explains just what it is, and why you should take notice of it.
-
Here's why the market is irrational – it's the City's faultBeginners' Guides The trouble with the financial services industry is that it is not interested in making money for you. It is interested in making money for itself. The best person to manage your money is you, says John Stepek. Here's why.
-
Portfolio building: How to go it alone and do it yourself
Beginners' Guides So you’ve decided to take charge of your own money. But before you invest a penny, you need to think about how you are going to put together your investment portfolio.
-
How do you know when a market is cheap?
Beginners' Guides The way to make money from investing is to buy when markets are cheap and sell when they're expensive. Here, John Stepek explains one simple way to tell when that is.
-
What you should know about corporate bondsBeginners' Guides Demand for corporate bonds has soared among private investors lately. But what are they, how do they work, and what should you look out for? Phil Oakley explains.
-
How to value companies that own lots of assets
Beginners' Guides For some asset-rich companies, it's not necessarily their earnings that makes them attractive investments, says Tim Bennett. Here, he explains the best way to work out how much you should pay for them.
-
How you can get an investing edge over the professionals
Beginners' Guides When it comes to research, most professional investors are lazy, says Phil Oakley. Here, he explains how spending a little time getting to know a firm's annual report can earn you big profits.
-
Three vital things you must know about commodities
Beginners' Guides 'Real' assets are popular with investors at the moment. But what are they and how do they fit in to your portfolio? John Stepek explains.
